| | phorylation Kinase erine/Threonine Kinase AGC CAMK CK1 CK1 STE | ID Unnamed Unnamed Unnamed Unnamed | Position 120 121 6 | Code S S | Kinase STE/STE-Unique/NIK | Peptide LKGGTKG <mark>S</mark> SQVGENV | Score 10.5 | Cutoff |
|-----------------|---|---|--|---|---|---|--|---|
| | phorylation Kinase erine/Threonine Kinase AGC CAMK CK1 CMGC STE | Unnamed Unnamed Unnamed Unnamed Unnamed | 120 121 6 | S S | STE/STE-Unique/NIK | LKGGTKGSSQVGENV | 10.5 | 8 |
| | IKL Atypical Other AUR CK2 CK2 CK2 CK2 CK2 CK2 KK | Unnamed Unnamed Unnamed Unnamed Unnamed Unnamed Unnamed Unnamed Unnamed | 49 82 223 260 120 121 145 167 385 498 167 332 395 401 | T T T S S S S S S S T T | STE/STE-Unique/NIK TKL/MLK/ILK TKL/MLK/ILK TKL/MLK/ILK TKL/MLK/ILK TKL/MLK/ILK TKL/MLK/TAK1 Atypical/PIKK/FRAP Other/AUR/AUR-A Other/AUR/AUR-A Other/AUR/AUR-A Other/AUR/AUR-B Other/AUR/IPL1-yeast Other/CK2/CK2a | KGGTKGSSQVGENVS **MDMTKTVEEKKTN STSKLKETLIADQTP PGPKLATTVEKEPEL ECMARACTLERERLK VPGSGKSTVRTLLK LKGGTKGSSQVGENV KGGTKGSSQVGENV KGGTKGSSQVGENVS AAKQKQKTPKSVKMQ KANDTRRSELINKFQ KQGNRMVSKGGRDTV ASNSHRYSAKPDEDH KANDTRRSELINKFQ LQRRLRASMVLLVGD GRDTVIITDYDGETD ITDYDGETDETEKNI | 11 3.778 4.444 3.889 4.667 3.889 5 9.9 6.667 5.357 3.929 5.179 6.069 6.069 6.684 3.691 4.057 | 8 3.556 3.556 3.556 3.556 5 8.11 5.8 3.536 3.536 3.536 3.536 3.536 5.69 6.211 2.927 2.927 |
| | NEK | Unnamed | 69 17 | S | Other/CK2/CK2b Other/IKK/IKKa | GAKSKLDSSDRQVPG KKTNGTDSVKGVFEN | 6.75 5.111 | 6.5 |
| | PEK | Unnamed | 44 | S | Other/IKK/IKKa | GGDDSSTSKLKETLI | 4 | 4 |
| | PLK | Enter seque | nce(s) in | FASTA fo | ormat | | | |
| ▼ ♥ ■ Ty ▶ ♥ | TK | MDMTKTVEEK KKSKKKRIQKP EYTGRQYFRA NDYSGIEGVYG GNRMVSKGGF DAEIRQAFLTG | KKTNGTDS PAQPSRPND RSNFFEMIK GLDDLLLSA RDTVIITDY GDIDLSSKA | /KGVFENS 0LKGGTKG 1LASLYDKI VPITSDLL DGETDETI SNSHRYS/ | TIPKVPTGQEMGGDDSSTSKL SSQVCENVSENYTGISKEAAK HLKECMARACTLERERLKRKLI IIDEYTLAESAEILLLQRRLRAS EKNIAFTVDTVRDVKDCGYDC AKPDEDHSWFKAK | KETLIADQTPLSVDNGAKSKLU QKQKTPKSVKMQSNLADKFKA LLVRALKPAVDFLTGIISGVPGS MVLLVGDVAQGKATTASSIEY ALAIDVQGKEFDSVTLFLRNEI | DSSDRQVPGPKI NDTRRSELINK GKSTIVRTLLKG LTLPVIYRSETTY DRKALADKHLR | ATTVEKEPELI FQQFVHETCL EFPAVCALAN /RLGQETASLC LVALSRHKSKI |

* Threshold setting is HIGH (FPRs of 2% for Ser/Thr kinases, FPRs of 4% for Tyr kinases)

Β

| | разо_от_кт Т32 | SH3 P107 SH2 Y131 | V334 Acid_ST_kin S349 Acid_ST_kin T401 Predicted Sites | | | | |
|-------|-------------------|----------------------------|--|------------------|--|--|--|
| Basop | ohilic ser | ine/threon | ine kinase group (Bas | o_ST_kin) | | | |
| | AMP_Ki | nase | Gene Card PRK | Gene Card PRKAA1 | | | |
| Site | <u>Score</u> | Percentile | Sequence | SA | | | |
| T32 | <u>0.5410</u> | 0.175 % | STIPKVPTGQEMGGD | 1.127 | | | |
| Acido | philic se | rine/threo | nine kinase group (Aci | d_ST_kin) | | | |
| C | asein Ki | nase 1 | Gene Card CSNK1G2 | | | | |
| Site | <u>Score</u> | Percentile | Sequence | SA | | | |
| S349 | <u>0.3457</u> | 0.077 % | <u>QGKATTASSIEYLTL</u> | 0.728 | | | |
| C | asein Ki | nase 2 | Gene Card CSNK2B | | | | |
| Site | <u>Score</u> | Percentile | Sequence | <u>SA</u> | | | |
| T401 | <u>0.3503</u> | 0.074 % | ITDYDGE T DETEKNI | 2.366 | | | |

Fig. S1 Phosphorylation predictions of the $_{XJ}TGB1$ protein by the GPS 2.1 program (A) and the Scansite Motif Scanner online server (B).

| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | MDMTKTVEEKKTNGTDSVKGVFENSTIPKVPTGQE MSDGLRTNHQNETPGVQSEK <mark>M</mark> ELRQ <mark>T</mark> TSDDTQNQADSGAKSHDTNTSRVDETAKTTDVKESPSGES | 35 66 0 |
|--|--|-------------------|
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | MGGDDSSTSKLKETLIADQTPLSVDNGAKSKLDSSDRQVPGPKLA LSGVSAVSGGTDK <mark>G</mark> EK <mark>S</mark> AVRKEAGESKESPKSVPSDGGEVKHVDTETKAKSKRKKKNKKTPKEGTS MNIFLVYNTMAIDKIVKS | 80 132 18 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | TTVEKEPELKPNVKKSKKKRIQKPAQPSRPNDLKGGTKGSSQVGENVSENYTGI KTTSESSSAKNVESKESKKQTKPKAVSPSSDTSKIASEVGSAKKATKKESKKQTKDKGSAEDLNAN DNRSQKQQSSKKKKNRKHGNKVVENSTNVGVPPNEGVTLRRVRSVESIDEIFTSN k k g e e | 134 198 73 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | SKEAAKOKOKTPKSVKMOSNLADKFKANDTRRSELINKFOQFVHETCLKSDFEYT TKLKAKASEQKGPTIPGTSAEASRIDLLQSSTAEKFTKNDVRRTALVNEFVAQIHKFCIEQGFEPT ORTPPAAEQLPOKOKOSKPPSVAKKHAANDKRRYEKADAFMNKIVEASRASGFOPT a k nd rr f f t | 189 264 129 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | GROYFRARSNFFEMIKLASLYDKHLKECMARACTLERERLKRKLLLVRALKPAVDFLTGIISGVPG GROYMRARANLFELVGLRNLYMEHLKKTAAKACNFTKDRIRRKLFLTSNHKPSVDFLVGIVSGVPG GONFKRCPANLFEKCKLRALYDKHLRVLHKDACDSEKERIAAKSFLHRSLRPNVDFKVGIVSGVAG g r n fe l ly hl ac r k l p vdf gi sgv g | 255 330 195 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | SGKSTIVRTLLKGEFPAVCALANPALMN.DYSGIEGVYGLDDLLLSAVPITSDLLIDEYTLAESA CGKSTLVRKLLDSPISCYVALANPATER.DYRGTSNVMTLDDLLLAKVPMSSDLLIVDEYTLAESA SGKSTLIRKLCS.EADAMCVLANPRLKETDYKGQSKTFTLQQVLLSIVPMTSDIVIVDEYTLAESA gkst r l lanp dy g l ll vp sd i deytlaesa | 320 395 260 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | EILLLORRLRASMVLLVGDVAQGKATTASSIEYLTLPVIYRSETTYRLGQETASLCSKQGNRMVSK BILLLORRVRSSLVLUVGDVAQGRSNNASNIEYLTLPVIYRKITSHRIGEETAKACSKQGNRIRSA ELLLLORKLQATFLVLFGDVAQGNAKTASSLEYLQFPVVFISKTSHRLGKHTAELCKKHCQAFEPG e lllqr 395 401 gdvaqg as eyl pv t rg ta ckg | 386 461 326 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | G.GRDTVIITDYDGETDETEKNIAFTVDTVRDVKDCGYDCALAIDVOGKEFDSVTLFLRNEDRKAL G.RKDKLILVDYEGETEETEKNLAFTEETRDDVKDCGYDCSLVSEVOGLEYESVTLFLRNTDRAAA SPEEDEIIWADYLGAADTTEKNIAFTKETVEDLRDAGVEASLVLETOGKEYESVTLFIRESDEAAM d i dyg tekn aft t d dg l qg e svtlfr d a | 451 526 392 |
| BSMV XJTGB1 PSLV TGB1 LRSV TGB1 Consensus | ADKHLRLVALSRHKSKLITRADAEIRQAFLTGDIDLSS.KASNSHRYSAKPDEDHSWFKAK SDHHKRTVSMTRHKSLLIIRAEQEIGQPFLMGELSVSSKRPSNAHVYSSE ADSHLRAVALTRHRKKLITRAEPGVQSSFLNGELKSKTSADSHKYESSKVSYADSSSAAAQ dhrvrhliira flg s s | 511 576 453 |

Β

Α

| | | | | | | | | | 39 | 95 | | | 401 | | | | | |
|--------------------|------|-----|------|-----|--------------------|--------------------|----|----|----|-----|----|----|---------|----|------|-----|------|---|
| _{XJ} TGB1 | SLCS | SKQ | GNRM | VSK | GG | RD' | ΓĪ | VΙ | I | ΓD | ΥD | GΕ | ΤD | Ε | TEKN | IAF | TVI | D |
| _{ND} TGB1 | SLCS | SKQ | GNRM | VSK | GG <mark>I</mark> | RD' | Γ | VΙ | ΙŢ | ΓD | ΥD | GΕ | ΤD | G | TEKN | IAF | TVI | D |
| _{NW} TGB1 | SLCS | SKQ | GNRM | VSK | GG <mark>I</mark> | K <mark>D</mark> I | K | VΙ | ΙŢ | [D | ΥD | GΕ | ΤD | ΡE | TEKN | IAF | TVI | D |
| _{BJ} TGB1 | SLCS | SKQ | GNRM | VSK | | KD' | Γ | VΙ | I | [D] | ΥD | GΕ | ΤD | ΡE | TEKN | IAF | TVI | D |
| _{cv} TGB1 | SLCS | SKQ | GNRM | VSK | .GG <mark>I</mark> | RD' | Γ | VΙ | Τſ | [D] | ΥD | GΕ | ΤD | Ε | TEKN | IAF | ΓΤVΙ | D |
| _{TY} TGB1 | SLCS | SKQ | GNRM | VSK | GG | RD' | Γ | VΙ | 1 | ΓD | ΥD | GΕ | ΤD | G | TEKN | IAF | ſΤVΙ | D |
| | | | | | | | | | _ | | | | _ | | 4 | | | |

Fig. S2 Alignment of the TGB1 proteins of the hordeiviruses (A) and amongst six sequenced BSMV strains (B).

| Table S | S1 Prime | rs used in | construction a | nd analysis | of biologicall | v active BSM | V Xiniiang cDN | A clones |
|---------|----------|------------|----------------|-------------|----------------|--------------|----------------|----------|
| | | | | | | J | J O . | |

| Primer | Primer sequence (5'-3') ^a | Position and description ^b | Purpose | |
|-------------|---|---|--|--|
| XJ-1 | TGTAATACGACTCACTATAGGTATGTAAGTTGCCTTTGGGTG | _{XJ} BSMV RNAa nt 1-22 | $pT7\alpha_{XJ}$ construction in combination with BS-32 | |
| XJ-2 | TGTAATACGACTCACTATAGGTAAAAGAAAAGGAACAACCCTG | _{XJ} BSMV RNAβ nt 1-23 | $pT7\beta_{XJ}$ construction in combination with BS-32 | |
| XJ-3 | TGTAATACGACTCACTATAGGTATAGCTTGAGCATTACCGTC | _{XJ} BSMV RNAy nt 1-22 | $pT7\gamma_{XJ}$ construction in combination with BS-32 | |
| CH-10 | GTATGTAAGTTGCCTTTGGGTGTA | _{XJ} BSMV RNAα nt 1-24 | pCaBS- α_{XJ} construction in combination with BS-26 | |
| CH-11 | GTAAAAGAAAAGGAACAACCCTGT | _{XJ} BSMV RNAβ nt 1-24 | pCaBS- β_{XJ} and its mutants construction in combination with BS-26 | |
| CH-12 | GTATAGCTTGAGCATTACCGTCGT | _{XJ} BSMV RNAy nt 1-24 | pCaBS- γ_{XJ} construction in combination with BS-26 | |
| BS-26 | CG <u>GGATCC</u> TGGTCTTCCCTTGGGGGGAC | _{XJ} BSMV RNAγ nt 2793-2775 (common to the 3' termini of BSMV gRNAs) | pCaBS- α_{XJ} , pCaBS- β_{XJ} , and pCaBS- γ_{XJ} construction | |
| BS-10 | GGTGCTTGATGCTTTGGATAAGG | _{XJ} BSMV RNAγ nt 1864-1886 | verification of BSMV genome by | |
| BS-32 | TGGTCTTCCCTTGGGGGGAC | _{XJ} BSMV RNAy nt 2790-2772 | RT-PCR | |
| TGB1-XhoIF | CCG <u>CTCGAG</u> CTATGGACATGACGAAAACTGTTGAGG | _{XJ} TGB1 nt 1-25 | pGDG- _{XJ} TGB1and its mutants | |
| TGB1-BamHIR | CG <u>GGATCC</u> TTATTTGGCCTTGAACCAACTGTGG | _{XJ} TGB1 nt 1536-1512 | construction | |
| TGB2-XhoIF | CCG <u>CTCGAG</u> CTATGAAGACCACAGTTG | _{XJ} TGB2 nt 1-16 | TCD TCD2 construction | |
| TGB2-BamHIR | CG <u>GGATCC</u> CTAGCCAATATCGCATAG | _{XJ} TGB2 nt 395-379 | pGD- _{XJ} TGB2 construction | |

| Primer | Primer sequence (5'-3') ^a | Position and description ^b | Purpose | |
|--------------|---|---------------------------------------|---------------------------------------|--|
| TGB3-XhoIF | CCG <u>CTCGAG</u> CTATGGCAATGCCTCATC | _{XJ} TGB3 nt 1-16 | pGDG-xJTGB3 and pGDR-xJTGB3 | |
| TGB3-BamHIR | CG <u>GGATCC</u> TTACCTTTTTGAAGAAAG | _{XJ} TGB3 nt 469-451 | construction | |
| TGB1-NdeIF | GGAATTC <u>CATATG</u> ATGGACATGACGAAAACTG | _{XJ} TGB1 nt 1-19 | | |
| TGB1-XhoIR | CTCGAGTTTGGCCTTGAACCAAC xJTGB1 nt 1533-1517 | | pE1- _{XJ} 1GB1 construction | |
| TGB3-BamHIF | CGGGATCCATGGCAATGCCTCATC xJTGB3 nt 1-16 | | nGEX-wTGB3 construction | |
| TGB3-XhoIR | CCG <u>CTCGAG</u> TTACCTTTTTGAAGAAAG | _{XJ} TGB3 nt 468-451 | pGEA- _{XJ} 1GB3 construction | |
| NbCK2α-NdeIF | GGAATTC <u>CATATG</u> ATGTCAAAAGCTCGTG | NbCK2α nt 1-16 | | |
| NbCK2a-XhoIR | CAA <u>CTCGAG</u> CTGCGTCCTCATCC | NbCK2α nt 999-986 | pE1- NOCK2α construction | |
| HvCK2α-NdeIF | GGAATTC <u>CATATG</u> ATGTCGAAGGCGAGGGTC | HvCK2α nt 148-165 | TT H-CV2. construction | |
| HvCK2α-SalIR | GC <u>GTCGAC</u> TTGCGGTCGTGC | HvCK2α nt 1146-1135 | pe1- nvCK2a construction | |

^a Underlined letters indicate restriction enzyme sites, gray covered letters show T7 promoter sequence.

^b Numbers correspond to target nucleotide positions; a reverse order of numbers indicates that the primer is complementary to the targeted sequences.

| Table S2 Pri | mers used for | site-specific | mutagenesis | of Xinjiang | RNAβ clones |
|--------------|---------------|---------------|-------------|-------------|---------------------------------------|
| | | | 0 | | · · · · · · · · · · · · · · · · · · · |

| Primer | Primer sequence (5'-3') ^a | Position and description ^b | Purpose | |
|-----------------|--|---------------------------------------|--|--|
| T395A-F | GGGACACAGTGATCATT <u>G</u> CTGATTACGATGGCG | _{XJ} BSMV RNAβ nt 1958-1990 | $pT7\beta_{XJ}TGB1_{T395A}$ and | |
| T395A-R | CGCCATCGTAATCAG <u>C</u> AATGATCACTGTGTCCC | _{XJ} BSMV RNAβ nt 1990-1958 | $pET{XJ}TGB1_{T395A}$ construction | |
| T395D-F | GGAAGGGACACAGTGATCATT <u>GA</u> TGATTACGATGGCGAAACAG | _{XJ} BSMV RNAβ nt 1954-1996 | $pT7\beta_{XJ}TGB1_{T395D}$ and | |
| T395D-R | CTGTTTCGCCATCGTAATCA <u>TC</u> AATGATCACTGTGTCCCTTCC | _{XJ} BSMV RNAβ nt 1996-1954 | pET- _{XJ} TGB1 _{T395D} construction | |
| T395E-F | GGAAGGGACACAGTGATCATT <u>GAA</u> GATTACGATGGCGAAACAG | _{XJ} BSMV RNAβ nt 1954-1996 | $pT7\beta_{XJ}TGB1_{T395E}$ and | |
| T395E-R | CTGTTTCGCCATCGTAATC <u>TTC</u> AATGATCACTGTGTCCCTTCC | $pET{XJ}TGB1_{T395E}$ construction | | |
| T401A-F | GATTACGATGGCGAA <u>G</u> CAGATGAAACGGAGAAAAATATCG | _{XJ} BSMV RNAβ nt 1978-2017 | $pT7\beta_{XJ}TGB1_{T401A}$ and | |
| T401A-R | CGATATTTTTCTCCGTTTCATCTG <u>C</u> TTCGCCATCGTAATC | _{XJ} BSMV RNAβ nt 2017-1978 | $pET{XJ}TGB1_{T401A}$ construction | |
| T401D-F | GATTACGATGGCGAA <u>GAC</u> GATGAAACGGAGAAAAATATCG | _{XJ} BSMV RNAβ nt 1978-2017 | $pT7\beta_{XJ}TGB1_{T401D}$ and | |
| T401D-R | CGATATTTTTCTCCGTTTCATC <u>GTC</u> TTCGCCATCGTAATC | _{XJ} BSMV RNAβ nt 2017-1978 | $pET{XJ}TGB1_{T401D}$ construction | |
| T401E-F | GATTACGATGGCGAA <u>GA</u> AGATGAAACGGAGAAAAATATCG | _{XJ} BSMV RNAβ nt 1978-2017 | $pT7\beta_{XJ}TGB1_{T401E}$ and | |
| T401E-R | CGATATTTTTCTCCGTTTCAT <u>CT</u> TCTTCGCCATCGTAATC | _{XJ} BSMV RNAβ nt 2017-1978 | $pET{XJ}TGB1_{T401E}$ construction | |
| T395A/ T401A -F | CACAGTGATCATT <u>G</u> CTGATTACGATGGCGAA <u>G</u> CAGATGAAACGG | _{XJ} BSMV RNAβ nt 1962-2005 | $pT7\beta_{XJ}TGB1_{T395A/T401A}$ and | |
| T395A/ T401A -R | A -R CCGTTTCATCTG <u>C</u> TTCGCCATCGTAATCAG <u>C</u> AATGATCACTGTG _{xJ} BSMV RNAβ nt 200 | | construction | |
| T395D/ T401A -F | CACAGTGATCATT GA TGATTACGATGGCGAA <u>G</u> CAGATGAAACGG | _{XJ} BSMV RNAβ nt 1962-2005 | $\begin{array}{l} pT7\beta_{XJ}TGB1_{T395D/T401A} \text{ and} \\ pET{XJ}TGB1_{T395D/T401A} \\ \text{construction} \end{array}$ | |
| T395D/ T401A -R | CCGTTTCATCTGCTTCGCCATCGTAATCATCATCACTGTG | _{XJ} BSMV RNAβ nt 2005-1962 | | |

| T395E/ T401A -F | CACAGTGATCATT <u>GAA</u> GATTACGATGGCGAA <u>G</u> CAGATGAAACGG | _{XJ} BSMV RNAβ nt 1962-2005 | $pT7\beta_{XJ}TGB1_{T395E/T401A}$ and $pET = TGP1$ |
|-----------------|--|--------------------------------------|--|
| T395E/ T401A -R | CCGTTTCATCTG <u>C</u> TTCGCCATCGTAATC <u>TTC</u> AATGATCACTGTG | _{XJ} BSMV RNAβ nt 2005-1962 | construction |

^a Underlined and bold letters indicate sequences altered by site-specific mutagenesis.

^b Numbers correspond to target nucleotide positions; a reverse order of numbers indicates that the primer is complementary to the targeted sequences.

| Identity of sequences (%) | | | | | | | |
|---------------------------|-------------|-------|-------|--|--|--|--|
| Strain | Full length | C | la | | | | |
| Strain | nt | nt | aa | | | | |
| ND18 | 99.82 | 99.85 | 99.65 | | | | |
| Туре | 99.66 | 99.82 | 99.56 | | | | |
| Norwich | 98.52 | 98.51 | 98.77 | | | | |
| Beijing | 95.18 | 94.96 | 96.66 | | | | |

Table S3 Sequence alignment of Xinjiang strain RNAa with different BSMV strains

Table S4 Sequence alignment of Xinjiang strain RNA β with different BSMV strains

| Identity of sequences (%) | | | | | | | | | |
|---------------------------|----------------|-------|-------|-------|-------|---------|-------|-------|-------|
| Strain | Full length βa | | TG | B1 | TG | B2 TGB3 | | B3 | |
| | nt | nt | aa | nt | aa | nt | aa | nt | aa |
| ND18 | 99.23 | 99.83 | 99.49 | 99.67 | 99.41 | 100 | 100 | 99.78 | 100 |
| Туре | 99.41 | 100 | 100 | 99.67 | 99.22 | 99.75 | 100 | 100 | 100 |
| Norwich | 95.85 | 99.16 | 100 | 95.72 | 93 | 97.2 | 99.24 | 95.27 | 93.55 |
| Beijing | 94.08 | 92.42 | 92.42 | 95.39 | 93.76 | 96.69 | 99.24 | 96.13 | 94.19 |

Table S5 Sequence alignment of Xinjiang strain RNA γ with different BSMV strains

| Identity of sequences (%) | | | | | | | | | | | |
|---------------------------|-------------|-------|-------|-------|-------|--|--|--|--|--|--|
| Strain | Full length |) | /a | γb | | | | | | | |
| | nt | nt | aa | nt | aa | | | | | | |
| ND18 | 98.78 | 98.92 | 99.38 | 97.6 | 96.73 | | | | | | |
| Туре | 87.82 | 83.74 | 83.83 | 99.35 | 99.35 | | | | | | |
| Norwich | 98.5 | 98.77 | 99.54 | 97.42 | 98.69 | | | | | | |
| Beijing | 94.36 | 95.02 | 96.92 | 94.55 | 94.12 | | | | | | |

| Systemic infectivity efficiency on Nicotiana benthamiana | | | | | | | | | | | | |
|--|--------------------------------|-----|-------|-------|-------|-------|-------|-------|----------------|----------------|----------------|--|
| | Mock | WT | T395A | T395D | T395E | T401A | T401D | T401E | T395A T401A | T395D T401A | T395E T401A | |
| Exp. 1 | 0 ^a /8 ^b | 7/8 | 6/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 2 | 0/8 | 7/8 | 6/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 3 | 0/8 | 7/8 | 5/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | |
| Systemic infectivity efficiency on barley | | | | | | | | | | | | |
| Exp. 1 | 0/8 | 6/8 | 5/8 | 0/8 | 4/8 | 1/8 | 0/8 | 4/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 2 | 0/8 | 6/8 | 3/8 | 0/8 | 2/8 | 2/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 3 | 0/8 | 6/8 | 4/8 | 0/8 | 4/8 | 1/8 | 0/8 | 4/8 | 0/8 | 0/8 | 0/8 | |
| Systemic infectivity efficiency on wheat | | | | | | | | | | | | |
| Exp. 1 | 0/8 | 7/8 | 6/8 | 0/8 | 6/8 | 4/8 | 0/8 | 5/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 2 | 0/8 | 7/8 | 5/8 | 0/8 | 5/8 | 3/8 | 0/8 | 5/8 | 0/8 | 0/8 | 0/8 | |
| Exp. 3 | 0/8 | 8/8 | 6/8 | 0/8 | 5/8 | 2/8 | 0/8 | 4/8 | 0/8 | 0/8 | 0/8 | |

Table S6 Systemic infectivity efficiency of XJBSMV phosphorylation related mutants on hosts

^a numbers of systemically infected plants ^b numbers of the total inoculated plants